Plain-English translation of NCT01957267 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Glaucoma is a serious eye disease that can lead to blindness if not caught early, but current diagnostic tests have important limitations. This study uses advanced imaging technology called optical coherence tomography (OCT) along with blood flow imaging to find better ways to diagnose glaucoma and track how it progresses over time. Researchers will compare the results from people with glaucoma to those with healthy eyes to see if these new imaging methods work better than what doctors currently use.
About half of all Americans with glaucoma don't know they have it because the disease is silent and develops slowly. Current eye tests are not reliable enough to catch glaucoma early or accurately track whether it's getting worse, so doctors need better tools to diagnose and monitor this sight-threatening condition.
You likely qualify if…
You likely don't qualify if…
You will visit the research clinic where doctors will perform several eye imaging tests, including advanced scanning technology to look at your optic nerve and blood flow in your eye. You may also have standard eye pressure measurements and vision field tests. The study is observational, meaning you won't receive any new medication — researchers are simply monitoring and photographing your eyes over time to see if the new imaging methods can better detect and track glaucoma.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States
Sponsor
Oregon Health and Science University
Collaborators
National Eye Institute (NEI)
Enrollment target
~249 participants
Started
September 2013
Primary completion
May 2031
Age range
40 Years – 85 Years
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chinmay Deshpande, M.Optom.
Oregon Health and Science University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.